Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 115.15 (+1.40), GALE: 1.49 (-0.02), EXAS: 27.60 (+0.39), ARIA: 6.81 (+0.15), MNKD: 5.68 (+0.18)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)
Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
GlobeNewswire - Thu Dec 11, 7:55AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that initial immunohistochemistry (IHC) screening data from the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS).
GALE: 1.49 (-0.02)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
Galena: I Am Bullish, However, Nobody Has Paid Me For My Stance
Kanak Kanti De - at Seeking Alpha - Tue Dec 09, 7:32AM CST
GALE: 1.49 (-0.02)
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
GlobeNewswire - Mon Dec 08, 6:05AM CST
-- Phase 1 results demonstrate GALE-401 reduces platelet counts with tolerable safety profile
GALE: 1.49 (-0.02)
This is Incredibly Good News for Breast Cancer Survivors
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 06, 11:08AM CST
Source: Komen Austin via Flickr . There are few, if any, medical diagnoses in life that are scarier than cancer. Based on data from the Centers for Disease Control and Prevention, cancer is now the second-leading cause of death in the United...
PFE: 31.42 (-0.03), GALE: 1.49 (-0.02)
Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
GlobeNewswire - Fri Dec 05, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that initial immunohistochemistry (IHC) screening data from the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) trial will be presented at the 2014 San Antonio Breast Cancer Symposium (SABCS). The IHC screening data identifies IHC HER2 1+ and 2+ patients to support the PRESENT study and a companion diagnostic for NeuVax. The conference is taking place December 9-13, 2014 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
GALE: 1.49 (-0.02)
InMed Pharma's Hiring of Tiberend Highlights Biotech Focus
ACCESSWIRE - Wed Dec 03, 9:32AM CST
WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (NASDAQ: GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
ADXS: 7.57 (+0.50), GWPH: 68.08 (+1.82), GALE: 1.49 (-0.02)
Why Galena Biopharma Inc. Stock Sank 13% in November
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 03, 7:00AM CST
GALE data by YCharts What: Shares of Galena Biopharma , a biopharmaceutical company focused on developing immunotherapies to treat cancer, sank 13% in November, based on data from S&P Capital IQ , following a weak earnings report and a...
GALE: 1.49 (-0.02)
Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter
GlobeNewswire - Tue Dec 02, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application for GALE-401 composition of matter. GALE-401 is a controlled release formulation of anagrelide for use in reducing platelet counts in patients with Myeloproliferative Neoplasms (MPNs).
GALE: 1.49 (-0.02)
Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
GlobeNewswire - Mon Dec 01, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 1 clinical trials of GALE-401, or Anagrelide Controlled Release, will be presented at the upcoming 56th American Society of Hematology (ASH) Annual Meeting & Exposition. The poster presentation will also include preliminary data from the ongoing GALE-401 Phase 2 trial in patients with elevated platelet counts due to myeloproliferative neoplasms (MPNs). The conference takes place December 5-9, 2014 at the Moscone Center in San Francisco, CA.
GALE: 1.49 (-0.02)
Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 6:05AM CST
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Oppenheimer 25th Annual Healthcare Conference. The presentation will take place on Wednesday, December 10, 2014 at 3:55 p.m. ET at the Crowne Plaza Hotel in New York.
GALE: 1.49 (-0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.81 (unch), CLRB: 3.02 (-0.05), MPX: 8.00 (-0.03), FATE: 4.90 (+0.23), TTPH: 38.86 (+0.53), PHMD: 1.46 (-0.03), BIND: 5.73 (+0.06), AXPW: 1.00 (-0.04), CANF: 3.70 (+0.01), SYN: 1.46 (-0.07), RNA: 18.76 (+0.10), CLIR: 7.63 (+0.16), VSCI: 0.76 (-0.07), OCRX: 5.77 (+0.02), GALE: 1.49 (-0.02), REI: 10.95 (+0.22), OGEN: 0.90 (-0.07), PTP: 73.65 (-0.03), FPRX: 26.12 (+0.07)
Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing
at The Street - Mon Nov 24, 8:39AM CST
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
GALE: 1.49 (-0.02)
Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
GlobeNewswire - Thu Nov 20, 3:20PM CST
-- Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014
GALE: 1.49 (-0.02)
Today In SA PRO: Wednesday, November 19
SA PRO Top Ideas - at Seeking Alpha - Thu Nov 20, 4:00AM CST
Top Idea: Magnetek by Dane Capital Management, LLC: Long / Micro-Cap / Electrical Equipment / GARP / Dividend Distribution / Buyside Author / 40% Upside Outstanding Performance Award Winner #1: Top Long idea on RCPT (Receptos) by Stephen...
MAG: 38.01 (+0.33), GALE: 1.49 (-0.02)
Wall Street Breakfast: Dollar General May Have To Divest 4,000+ Stores
Wall Street Breakfast - Seeking Alpha - Wed Nov 19, 5:30AM CST
Economy The Ebola epidemic in west Africa has led mining companies in the region to put expansion plans on hold, delaying the rollout of jobs meant for residents of the countries hardest hit by the virus. ArcelorMittal (NYSE: MT ) has delayed a...
BX: 34.01 (+0.05), KKR: 23.14 (+0.24), BSX: 13.13 (+0.07), JNJ: 104.59 (+0.31), PBR: 7.60 (-0.11), T: 33.96 (-0.07), DLTR: 69.86 (-0.20), APO: 23.33 (-0.09), SPY: 207.77 (+0.02), TRP: 48.79 (unch), GALE: 1.49 (-0.02), DG: 69.86 (+0.31), TMUS: 26.67 (+0.07), PGRE: 18.46 (-0.07), RIO: 45.02 (+0.13), FDO: 79.14 (-0.01), DISH: 72.63 (+0.54), MT: 11.08 (-0.09), GS: 195.89 (+0.39), OME: 10.00 (+0.09), QQQ: 104.30 (+0.09), VZ: 47.67 (unch), PETM: 81.16 (+0.03)
Galena completes enrollment in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 12:34PM CST
GALE: 1.49 (-0.02)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 16.23 (-0.23), GERN: 3.06 (+0.05), TKMR: 13.97 (+0.14), GALE: 1.49 (-0.02), XOMA: 3.68 (+0.11), EXEL: 1.29 (-0.01)